Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Investor Wire

CRIS Quote, Trading Chart, Curis Inc.


home / stock / cris / cris quote

$9.98 Last:

-1.48% Change Percent:

$9.93 Open:

$9.98 Previous Close:

$10.15 High:

$9.55 Low:

385,459 Volume:

03/03/2021 12:35:10 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2021-03-039.939.9810.159.55385,459
2021-03-0210.1910.1310.3510.011,287,139
2021-03-0110.235410.4310.5310.011,716,848
2021-02-269.89.8410.099.391,332,235
2021-02-259.839.7510.149.461,120,970
2021-02-249.859.9310.179.62806,169
2021-02-239.759.699.989.011,699,947
2021-02-2210.134810.0810.259.861,843,835
2021-02-1910.6710.2710.6710.16897,475
2021-02-1810.6710.5110.9810.271,441,199
2021-02-1710.3511.0711.0910.252,144,855
2021-02-1610.810.5710.8210.21,542,245
2021-02-1510.5410.810.910.122,148,908
2021-02-1210.5410.810.910.122,127,733
2021-02-1110.943610.8712.2910.76,726,694
2021-02-1010.029.7610.19.341,535,262
2021-02-099.959.76510.049.571,697,480
2021-02-0810.319.9610.559.791,934,068
2021-02-0510.3410.2410.34999.9151,054,709
2021-02-0410.618810.3810.6510.16883,153
Stock Information

Curis Inc. Company Name:

CRIS Stock Symbol:

NASDAQ Market:

Curis Inc. Website:

CRIS Quote, Trading Chart, Curis Inc.

MENU
CRIS CRIS Quote CRIS Short CRIS News CRIS Articles CRIS Message Board
Get CRIS Alerts

News, Short Squeeze, Breakout and More Instantly...

Stock Investor Wire
RECENT CRIS NEWS
  • CRIS - Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

    Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies - Amends existing protocol of ongoing Phase 1 study in R/R NHL - - Initial data expected in the fourth quarter of 2021 - P...

  • CRIS - Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

    Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes - Phase 2 study sponsored by investigators at Universität Leipzig in Germany - ...

  • CRIS - Curis to Present at B. Riley Securities Virtual Oncology Investor Conference

    Curis to Present at B. Riley Securities Virtual Oncology Investor Conference PR Newswire LEXINGTON, Mass. , Jan. 14, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment o...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Sign up or login to continue

Sign up or login to continue.


Forgot password?




WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News